Amneal launches generic Invega

Amneal is introducing its generic Invega (paliperidone) extended-release tablets. The drug will be available in dosage strengths of 1.5 mg, 3 mg, 6 mg and 9 mg.

Janssen is the brand manufacturer of Invega, which is used to treat schizophrenia in adults and adolescents (12-17 years of age).

“We are pleased to have received approval on and launched a generic version of Invega, one of the 15 complex products we expect to launch over a 24-month period,” Amneal co-CEO Chintu Patel said. “With a diverse pipeline of more than 170 products, we will continue to deliver additional complex product approvals that expands our portfolio and provides patient access to affordable generic medicines.”

Paliperidone extended-release tablets had a market value of approximately $373 million for the 12 months ended July 31, according to IQVIA.